BISPECIFIC T-CELL ENGAGER
Talvey (talquetamab-tgvs) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with relapsed or refractory multiple myeloma.
These insights are based on 200 comments about Talvey from MyMyelomaTeam members. These are the experiences of a small number of people and are not meant to be medical advice.
Talvey works by attaching to a target on myeloma cells and to T cells, which are part of the immune system that help fight disease. This brings the T cells close to the cancer cells and activates them. The T cells then release signals called cytokines and help kill the myeloma cells.
This may help control relapsed or refractory multiple myeloma in adults who have already received at least four prior treatments.
Doctors prescribe Talvey for adults with relapsed or refractory multiple myeloma after at least four prior treatments, including:
The medication is given as an injection under the skin by a healthcare professional. Treatment starts with smaller step-up doses over the first few days. After that, it is given either once every week or once every two weeks.
It is not given at home.
Members who use Talvey often say it helps to prepare for side effects, especially changes in taste, dry mouth, skin peeling, and nail problems. Many also suggest keeping close contact with your care team about reactions, treatment timing, and how well the drug is working for you.
Prepare for step-up dosing and hospital monitoring.
“Talvey requires hospital monitoring for the step-up doses. Then it’s either every week injection or every two weeks.”
Expect taste changes and find ways to keep eating.
“The sense of taste is the first to go.”
Use simple products for dry mouth and skin care.
“Mouth and throat dryness became more manageable when I used Biotene mouthwash, moisturizing gel, and spray, along with ACT lozenges. For dry skin, I used CeraVe cream and Dove soap.”
Connect with others who understand life with multiple myeloma. Join MyMyelomaTeam for free.
In clinical studies of Talvey in adults with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy, common side effects were reported often. The most common side effects occurred in about 21 percent to 83 percent of people.
Talvey can cause serious side effects that require immediate medical attention. These include:
Get medical help right away if you think you are having a serious reaction.
Johnson & Johnson, the manufacturer of Talvey, offers the J&J withMe Savings Program. Eligible people with commercial insurance may pay as little as $5 per dose.
The J&J withMe Savings Program also offers Care Navigator support to help guide you through the treatment journey, including help with support resources, community connections, and cost. To learn more, visit the Talvey Savings and Support page or call 833-565-9631.
Before each step-up dose of Talvey, you will receive medicines to help lower the risk of cytokine release syndrome.
Because of the risk of CRS and neurologic problems, you will need to stay in the hospital for 48 hours after each step-up dose. The step-up dosing schedule includes the first two or three smaller doses and the first full treatment dose.
Do not drive, use heavy machinery, or do dangerous activities during the step-up dosing schedule and for 48 hours after it ends. Also avoid these activities if you have dizziness, confusion, tremors, sleepiness, or other neurologic symptoms until they go away.
Tell your doctor if you have any allergies to talquetamab-tgvs or any ingredients in Talvey.
Tell your doctor about all medicines you take, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Also let your doctor know if you have had recent infections or nervous system problems in the past.
Do not take Talvey if you have had a serious allergic reaction to talquetamab-tgvs or any of its ingredients.
If a dose is delayed, your doctor may need to adjust your schedule. In some cases, you may need to repeat the step-up dosing.
If you are pregnant, planning to become pregnant, or breastfeeding while taking Talvey, talk with your doctor about the risks and benefits. Talvey may harm the baby. Your doctor should check if you are pregnant before you start treatment.
If you can become pregnant, use birth control during treatment and for three months after your last dose. Do not breastfeed during treatment and for three months after your last dose.
These answers are fact-checked by our editorial staff.
How effective is Talvey?
In a study of people with relapsed or refractory multiple myeloma who had received at least four prior lines of treatment, about 73 percent of people responded to Talvey when given once a week or once every two weeks. About 33 percent to 35 percent had a complete response. Talvey started working in about 1.2 to 1.3 months.
For people who responded, the response lasted about 9.5 months with weekly dosing. With dosing every two weeks, about 85 percent of people maintained their response for at least nine months.
How long does Talvey take to work for multiple myeloma?
Talvey started working (median time to first response) in about 1.2 months with weekly dosing and about 1.3 months with dosing every two weeks. Some people responded sooner, and some took longer.
Why do people with multiple myeloma need step-up dosing and hospital monitoring with Talvey?
Talvey uses step-up dosing to lower the risk of a reaction called cytokine release syndrome, which can be serious. People stay in the hospital for 48 hours after each step-up dose so doctors can watch for side effects. People also get medicines before each step-up dose to help lower the risk of CRS.
In studies, CRS happened in 76 percent of people, most often after the first doses.
On MyMyelomaTeam, people share their experiences with multiple myeloma, get advice, and find support from others who understand.
Learn more about Talvey and multiple myeloma care:
More resources from MyMyelomaTeam that mention Talvey
Become a member to get even more